» Articles » PMID: 18477997

Technology Insight: Adult Mesenchymal Stem Cells for Osteoarthritis Therapy

Overview
Specialty Rheumatology
Date 2008 May 15
PMID 18477997
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the high prevalence and morbidity of osteoarthritis (OA), an effective treatment for this disease is currently lacking. Restoration of the diseased articular cartilage in patients with OA is, therefore, a challenge of considerable appeal to researchers and clinicians. Techniques that cause multipotent adult mesenchymal stem cells (MSCs) to differentiate into cells of the chondrogenic lineage have led to a variety of experimental strategies to investigate whether MSCs instead of chondrocytes can be used for the regeneration and maintenance of articular cartilage. MSC-based strategies should provide practical advantages for the patient with OA. These strategies include use of MSCs as progenitor cells to engineer cartilage implants that can be used to repair chondral and osteochondral lesions, or as trophic producers of bioactive factors to initiate endogenous regenerative activities in the OA joint. Targeted gene therapy might further enhance these activities of MSCs. Delivery of MSCs might be attained by direct intra-articular injection or by graft of engineered constructs derived from cell-seeded scaffolds; this latter approach could provide a three-dimensional construct with mechanical properties that are congruous with the weight-bearing function of the joint. Promising experimental and clinical data are beginning to emerge in support of the use of MSCs for regenerative applications.

Citing Articles

Ugonin P facilitates chondrogenic properties in chondrocytes by inhibiting miR-3074-5p production: implications for the treatment of arthritic disorders.

Chang T, Ho T, Lin Y, Thuong L, Lai K, Tsai C Int J Biol Sci. 2025; 21(4):1378-1390.

PMID: 39990652 PMC: 11844289. DOI: 10.7150/ijbs.108789.


Safety assessment of equine allogeneic tenogenic primed mesenchymal stem cells in horses with naturally occurring tendon and ligament injuries.

Carlier S, Depuydt E, Van Hecke L, Martens A, Saunders J, Spaas J Front Vet Sci. 2024; 11:1282697.

PMID: 38468694 PMC: 10925754. DOI: 10.3389/fvets.2024.1282697.


Expanding the therapeutic potential of : a review of its pharmacological applications in musculoskeletal diseases.

Ye Z, Liu Y, Song J, Gao Y, Fang H, Hu Z Front Pharmacol. 2023; 14:1276038.

PMID: 38116081 PMC: 10728493. DOI: 10.3389/fphar.2023.1276038.


Polymeric biomaterials: Advanced drug delivery systems in osteoarthritis treatment.

Liu L, Tang H, Wang Y Heliyon. 2023; 9(11):e21544.

PMID: 38034809 PMC: 10682535. DOI: 10.1016/j.heliyon.2023.e21544.


Exploiting the Features of Short Peptides to Recognize Specific Cell Surface Markers.

Buonocore M, Grimaldi M, Santoro A, Covelli V, Marino C, Napolitano E Int J Mol Sci. 2023; 24(21).

PMID: 37958593 PMC: 10650159. DOI: 10.3390/ijms242115610.